Status:
COMPLETED
Schizophrenia Treatment Adherence Investigation (STAI)
Lead Sponsor:
Janssen-Cilag Pty Ltd
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.
Detailed Description
The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. Observation...
Eligibility Criteria
Inclusion
- Clinical diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV
- Currently treated in an outpatient clinic
- Able to provide informed consent
- Concurrent enrolment in clinical trials is acceptable
- Have completed all questions on the Drug Attitude Inventory (DAI-10) and Medication Adherence Rating Scale (MARS) survey
Exclusion
- N/A
Key Trial Info
Start Date :
July 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT01001481
Start Date
July 1 2007
End Date
September 1 2009
Last Update
April 9 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.